CureVac’s Stock Market Journey Concludes Following BioNTech Acquisition

The final chapter for Tübingen-based mRNA pioneer CureVac on public markets is now written. A turbulent period in German stock market history, which began with significant promise during the vaccine race, will formally end on January 16, 2026, when its shares are permanently removed from the Nasdaq exchange. This follows the company’s $1.25 billion acquisition by its rival, BioNTech.

Shareholder Terms and Transition

For investors, the transition is largely complete. Those who accepted the exchange offer received 0.05363 BioNTech American Depositary Shares (ADS) for each CureVac share they held. At the time the deal was announced, this ratio represented an approximate 55% premium to CureVac’s average trading price.

By the expiration of the offer in December 2025, nearly 87% of outstanding shares had been tendered. To gain full ownership, BioNTech has initiated a squeeze-out procedure for the remaining 13.25% of equity. Shareholders who did not participate will receive the same compensation as those who accepted the original exchange offer.

The Delisting Timeline

Trading in CureVac stock was effectively suspended as of January 6, 2026. On that date, the company confirmed the completion of its reorganization following BioNTech’s exchange offer and formally requested the delisting from the U.S. Securities and Exchange Commission (SEC).

Should investors sell immediately? Or is it worth buying CureVac?

The formal and permanent removal of the ticker symbol CVAC will occur on Friday, January 16. Subsequently, the successor entity, CureVac Merger B.V., intends to terminate the registration of its shares, which will end all ongoing public reporting obligations.

A New Strategic Era Under BioNTech

The acquisition has triggered a comprehensive leadership overhaul. CureVac’s entire executive board has resigned collectively. Management authority has now transferred to BioNTech leadership, including CEO and co-founder Professor Ugur Sahin.

Strategically, the merger consolidates German mRNA expertise. Beyond ending costly patent disputes, BioNTech gains valuable assets such as CureVac’s “RNA Printer” production capabilities. A legal settlement reached with GSK in August 2025, involving payments totaling around $500 million, will now be managed within the enlarged corporate group.

Investor attention now shifts exclusively to BioNTech’s integration efforts. Initial concrete insights into potential synergies are anticipated with the release of the Q4 2025 financial report, scheduled for late February 2026. Furthermore, data from the acquired glioblastoma program (CVGBM), expected around mid-2026, may provide early indications of the operational value of this strategic purchase.